HOME >> MEDICINE >> NEWS
Targeted therapy shows significant benefits over standard treatment for advanced kidney cancer

ATLANTA According to a new study, the drug sunitinib malate (Sutent) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.

"This drug has shown more activity as a single agent against advanced kidney cancer than any other drug I've studied in the past 15 years," said the study's lead author Robert J. Motzer, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). "I continue to be encouraged by its effectiveness in treating patients with this aggressive disease," said Dr. Motzer, who is a leader in the treatment of kidney cancer and conducted the earliest clinical trials on sunitinib (initially referred to as SU11248).

Interferon-alpha (IFN-) is one of the standard treatments for advanced kidney cancer, however only about 15 percent of patients respond to this immunotherapy. Sunitinib targets receptors on kidney cancer cells that may play a role in tumor growth and the development of blood vessels that feed a tumor. Previous clinical trials, also led by Dr. Motzer, showed that sunitinib caused some renal cell cancers to shrink, but this study is the first to demonstrate its effectiveness as a first-line therapy compared with standard cytokine therapy with IFN-.

The current randomized trial included 750 patients over the age of 60, half of whom were treated with a six-week cycle of sunitinib and half of whom were treated with a six-week cycle of the current treatment standard, IFN-. The primary endpoint of the trial was a comparison of progression-free survival between sunitinib and IFN- as assessed by independent third-party review. The median progression-free survival for treatment with sunitinib was 11 months, compared with 5 months following treatment with IFN-. This outcome was statistical
'"/>

Contact: Maria Connizzo
mediastaff@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
4-Jun-2006


Page: 1 2

Related medicine news :

1. Targeted, oral agent Enzastaurin shows favorable results
2. Targeted initiatives can encourage people to walk more
3. Targeted nanoparticles incorporating siRNA offer promise for cancer treatment
4. Targeted cancer drugs may work by disrupting balance of cellular signals
5. Targeted melanoma education of high risk groups improves screening
6. Targeted lymph node examination improves staging of colon cancer
7. Targeted cancer drug combined with low-dose chemotherapy shrinks tumors, slows ovarian cancer
8. Chemotherapy with bevacizumab increases risk of blood clots in arteries
9. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
10. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
11. Hormone therapy offers new hope for ovarian cancer patients

Post Your Comments:
(Date:4/24/2015)... AK (PRWEB) April 24, 2015 As ... (#MOTMC2015) and the unique sacrifices of these young men ... for Service members, Veterans and their Families” presents a ... training is designed to gain a better understanding of ... health and wellness. For those – civilian and military ...
(Date:4/24/2015)... New York, New York (PRWEB) April 24, 2015 ... continue to move forward in the federal ... of South Carolina. According to court documents, the ... Status Report on April 16th detailing, among other ... The report notes that counsel for both plaintiffs ...
(Date:4/24/2015)... Lowcostcarinsuranceprice.com has released a new blog post ... for senior citizens . , Senior citizens may ... mean that they cannot find affordable coverage. By comparing ... the right coverage for their cars at the best ... http://lowcostcarinsuranceprice.com/ provides free leads from various agencies that ...
(Date:4/24/2015)... Vancouver, BC (PRWEB) April 24, 2015 ... Albert Yuzpe, Olive Fertility co-founder and co-director, has been ... Fertility Preservation at the Evening of Hope Gala. ... to recognize Dr. Albert Yuzpe, who has been at ... past 43 years,” says Jessica Séguin, Executive Director of ...
(Date:4/24/2015)... ON (PRWEB) April 24, 2015 ... safe, informed and legal access to medical cannabis, is ... are properly supported when advising patients. , NAC is ... Certificate Program. With a $250,000 grant, NAC will be ... program. , "Our goal is to help Canadians gain ...
Breaking Medicine News(10 mins):Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3Health News:Low Cost Auto Insurance Quotes for Senior Citizens 2Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2
(Date:4/24/2015)... 24, 2015  Elekta has CE marked the latest ... system , enabling European clinics to deliver a sophisticated ... including advanced 3D planning, IMRT, VMAT and stereotactic planning ... Monaco ® v5.10 provides ... efficiency. Advancements in 3D planning as well as the ...
(Date:4/23/2015)... -- ResMed Inc. (NYSE: RMD ) today announced results ... the quarter was $422.5 million, a 6 percent increase ... 13 percent increase on a constant currency basis).  Net ... compared to the quarter ended March 31, 2014.  Diluted ... increase of 2 percent compared to the quarter ended ...
(Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:Elekta CE marks for Monaco v5.10 treatment planning system 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
Cached News: